Green Journals

Year	A	B
2026	✓	✓
2025	✓	✓
2024	✓	✓
2023	✓	✓
2021/2022	✓	✓
2020	✓	✓
2019		✓
2018

Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”

Jice Wang

2026-10-30

DOI: 10.3350/cmh.2026.0229

Fine-tuning cholesterol metabolic reprogramming via ERLIN1 in hepatocellular carcinoma: Correspondence to editorial on “Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma”

Yiming Zhang, Fuchu He, Chunyan Tian et al.

2026-10-30

DOI: 10.3350/cmh.2026.0335

Letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”

Shudan Chen, Xinhui Zhan, Liyuan Zhang et al.

2026-10-30

DOI: 10.3350/cmh.2026.0223

Immunotherapy-resistant subtype with heterogeneity of single cancer cells

Xin Li, Daojun Li, Kejun Yan et al.

2026-10-30

DOI: 10.3350/cmh.2026.0253

Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”

Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Seung Up Kim

2026-10-30

DOI: 10.3350/cmh.2026.0239

Correspondence to letter to the editor on “DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα”

Hyun Ahm Sohn, Hanyong Go, Won Kim et al.

2026-10-30

DOI: 10.3350/cmh.2026.0292

Correspondence to letter to the editor on “Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: significant role of alpha-fetoprotein”

Dongman Yu, Yeongseok Hwang, Gi-won Song et al.

2026-10-30

DOI: 10.3350/cmh.2026.0234

Normal-weight MASLD: diagnostic discordance is evident, but prognostic inference remains unsettled

Yuanyuan Liu

2026-10-29

DOI: 10.3350/cmh.2026.0473

Discordant FIB-4 and Liver Stiffness in MASLD: Implications for Risk Stratification, Generalizability, and Clinical Decision-Making: Correspondence to Authors’ reply

Jiajing Zhao, Liping Liu

2026-10-29

DOI: 10.3350/cmh.2026.0247

Real-world evidence speaks louder than biological plausibility. Editorial on “Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study”

Tian-Yi Ren, Jian-Gao Fan

2026-10-29

DOI: 10.3350/cmh.2026.0966

Journal Report

Journal Information

Classification History

Recent Articles

Clarifying response thresholds and regional reporting in metabolic dysfunction-associated steatotic liver disease cost-effectiveness: Letter to the Editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”

Fine-tuning cholesterol metabolic reprogramming via ERLIN1 in hepatocellular carcinoma: Correspondence to editorial on “Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma”

Letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”

Immunotherapy-resistant subtype with heterogeneity of single cancer cells

Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”

Correspondence to letter to the editor on “DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα”

Correspondence to letter to the editor on “Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: significant role of alpha-fetoprotein”

Normal-weight MASLD: diagnostic discordance is evident, but prognostic inference remains unsettled

Discordant FIB-4 and Liver Stiffness in MASLD: Implications for Risk Stratification, Generalizability, and Clinical Decision-Making: Correspondence to Authors’ reply

Real-world evidence speaks louder than biological plausibility. Editorial on “Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study”